



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Neil H. Bander
Serial No. : 09/929,665
Filed : August 13, 2001
Title : TREATMENT AND DIAGNOSIS OF PROSTATE CANCER

Art Unit : 1643
Examiner : Stephen L. Rawlings
Conf. No. : 9976

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant requests consideration of the references listed on the attached PTO-1449 form. A copy of a communication from the European Patent Office (a Notice of Opposition with the Opposition Brief) in a counterpart application is also enclosed.

This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance. I, the undersigned, hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated December 19, 2006, which is not more than three months prior to the filing of this statement.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2/2/07
Date of Deposit

Signature

Terri L. Knox
Typed or Printed Name of Person Signing Certificate

Applicant : Neil H. Bander
Serial No. : 09/929,665
Filed : August 13, 2001
Page : 2 of 2

Attorney's Docket No.: 21052-003009 / 1912-27 (US)

Please apply any charges or credits to Deposit Account No. 06-1050, referencing
Attorney's Docket Number 21052-003009.


Respectfully submitted,

Date: 2/2/07



Laurie Butler Lawrence
Reg. No. 46,593

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

 Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 21052-003009	Application No. 09/929,665
	Applicant Neil H. Bander			
	Filing Date August 13, 2001		Group Art Unit 1643	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	08/621,399		Murphy et al.			
	AB						

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AC	WO 96/08570	03/21/1996	WIPO				
	AD							

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	AE	Janeway and Travers, Immuno Biology 3 rd Ed. (1997), extracts from chapters 3, 8, and 13
	AF	Hopp et al., "A Computer Program for Predicting Protein Antigenic Determinants", Mol. Immunol. (1983) 20:4pp.483-489
	AG	Persiani et al., "In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for stage-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma", Cancer Immunol Immunother (1989) 29:pp. 167-170
	AH	Rajasekaran et al., "A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen", Molecular Biology of the Cell (December 2003) 14: pp. 4835-4845
	AI	Tazzari et al., "An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and a saporin 6: effect on T lymphocytes and hemopoietic cells", Cancer Immunol Immunother (1988) 26: pp 231-236
	AJ	Usui et al., "Evaluation of Ricin a Chain-Containing Immunotoxins Directed Against Glycolipid and Glycoprotein on Mouse Lymphoma Cells", Acta Med Okayama (1994) 48(6):pp 305-309
	AK	Wiedlocha et al., "Specific Killing of Mouse Leukemic Cells with Ricin A-Chain Immunotoxin", Archivum Immunologiae et Therapeutic Experimentalis (1989) 37:pp 101-113
	AL	Wiels et al., "Properties of Immunotoxins against a Glycolipid Antigen Associated with Burkitt's Lymphoma", Cancer Research (January 1984) 44:pp. 129-133

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	